18 hrs ago
Idenix Pharmaceuticals, Inc.at Oppenheimer 24th Annual Healthcare Conference
Idenix Pharmaceuticals, Inc. Idenix Pharmaceuticals, Inc.at Oppenheimer 24th Annual Healthcare Conference December 10, 2013 4:30 PM ET Today is the 24th Oppenheimer Healthcare Conference.
Mon Dec 09, 2013
Idenix Pharmaceuticals Announces Declaration of Senior Party in a...
Idenix Pharmaceuticals, Inc. , a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the United States Patent and Trademark Office declared a patent interference between Idenix's U.S. Patent 7,608,600 and Gilead Sciences, Inc.'s U.S. Patent Application ... (more)
Mon Dec 02, 2013
Idenix Pharmaceuticals' Management Presents at Deutsche Bank BioFEST Conference
So I had some questions for you guys today, but I am going to start with obviously some of the press releases that you had this morning and I just want you in your own words to walk us through kind of now how we look at the infringement case along with the US PTO case and give us the context thereon.
Idenix Pharmaceuticals Files Patent Infringement, Interference Lawsuits Against Gilead Sciences
Idenix Pharmaceuticals today announced that it has filed two lawsuits against Gilead Sciences, Inc. : a patent infringement lawsuit in the United States District Court in Boston, Massachusetts and a separate patent infringement and interference lawsuit in the United States District Court in Wilmington, Delaware.
Idenix Pharmaceuticals Initiates Enrollment in Phase II Study of...
Idenix Pharmaceuticals today announced the initiation of patient enrollment in the phase II HELIX-2 clinical trial evaluating an all-oral, direct-acting antiviral HCV combination regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir, a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and ... (more)
Tue Nov 26, 2013
Idenix Pharmaceuticals, Inc. To Present At Two Upcoming Healthcare Conferences
Idenix Pharmaceuticals, Inc. , announced today that Idenix management will participate in a fireside chat discussion at the 2013 Deutsche Bank BioFEST on Monday, December 2, 2013, at 10:45 a.m. ET at the Four Seasons Hotel in Boston, MA.
Thu Nov 14, 2013
Seth Klarman's Baupost Group increases Idenix stake, rejiggers $4B stock portfolio
Boston-based hedge fund manager Baupost Group lightened its portfolio of U.S. stocks to $3.5 billion in the third quarter, reducing its stake in a half dozen large companies while increasing its holdings in four firms, including Cambridge-based Idenix Pharmaceuticals.